EnglishFrançais EspañolРусский
Search
WecLac® Individual Clinical Strains
Clinically Studied
SCI/Patent Supported

Home > Products > WecLac® Individual Clinical Strains > Bifidobacterium breve

Bifidobacterium breveBBr60

Potency

600B CFU/g


Source of Strain

Healthy infant intestines


Deposit Number

PTA-126819(ATCC) No.12915(CGMCC)

Functions
  • Gastrointestinal Health
  • Metabolic Health
  • Emotional Health
  • Maternal & Child Health
  • Immune Health
  • Oral Health
References

[1]Ye Z, Liang L, Xu Y, Yang J, Li Y. Probiotics Influence Gut Microbiota and Tumor Immune Microenvironment to Enhance Anti-Tumor Efficacy of Doxorubicin. Probiotics Antimicrob Proteins. 2023 Apr 11. doi: 10.1007/s12602-023-10073-7. Epub ahead of print. PMID: 37040014.

[2]Dong Y, Han M, Fei T, Liu H, Gai Z. Utilization of diverse oligosaccharides for growth by Bifidobacterium and Lactobacillus species and their in vitro co-cultivation characteristics. Int Microbiol. 2023 Nov 9. doi: 10.1007/s10123-023-00446-x. Epub ahead of print. PMID: 37946011.

Introduction

Diarrhea apparent efficiency

In a randomized, double-blind, placebo-controlled trial of children with diarhea, the tested children were randomly divided into BLa80 probiotic intervention group and control group. After 72 hours of intervention, The marked and total effective rates of the lG were significantly higher than those of the CG.

Subjects

Dosage: Bifidobacterium lactis BLa80.5x109 CFU/sachet.2g/sachet

ltemsIG(n=58)cG(n=53)valuesP values
No. of marked31(53.4)10(18.9)
efficiency[n(% )]*
No.of normal18(31.0)14(26.4)21.6<0.001< /td>
efficiency[n(%)]*<< /td>
No. of inefficiency[n(%)]*9(15.6)29(54.7)
No.of total efficiency[n(%)]*49(84.4)124(45.3)18.901<0.001< /td>
In BLa80 group, the pathological changesof crypt injury, infiltration, ulcer and edema of colonic epithelium were alleviated
Specialization Advantages
  • 40,000+ Strain Resources
  • GRAS certified
  • Allergen free
  • SCI / Patent supported
  • High survivability
  • Non-GMO verified
  • Clinically studied
  • High colonisation
  • Precise function
Industrialization Advantages
  • High potency
  • Low water activity
  • Cost-effectiveness
  • High stability
  • Fast delivery
  • cGMP standard
  • Excellent batch stability
  • Stable supply chain
  • Advanced equipment
Application
  • Dietary Supplement
  • Food
  • Dairy
  • Precision Medicine
  • Personal Care
  • Feed Additive/Pet
WecLac® Individual Clinical Strains
  • Bifidobacterium longum subsp. longum BL21
  • Weizmannia coagulans BC99
  • Lacticaseibacillus paracasei LC86
  • Lactobacillus acidophilus LA85
  • Bifidobacterium animalis subsp. lactis BLa80
  • Lactiplantibacillus plantarum Lp05
  • Pediococcus acidilactici PA53
  • Lacticaseibacillus rhamnosus LRa05
  • Akkermansia muciniphila Akk11
    • No. 1033 Longqiao Road, Wujiang Economic and Technological Development Zone, Jiangsu Province, China
    Online Message
    Wecare Probiotics
    EnglishFrançais EspañolРусский
    Leave a Message